🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

Krystal Biotech director sells over $3.2 million in company stock

Published 2024-05-22, 06:22 p/m
KRYS
-

In a recent transaction, Julian S. Gangolli, a director at Krystal Biotech , Inc. (NASDAQ:KRYS), sold a substantial amount of company stock, signaling a notable change in his holdings in the biotechnology firm. The transaction, which took place on May 20, 2024, involved the sale of 20,000 shares at an average price of $22.75, as well as the sale of shares at varying prices resulting in a total sale value exceeding $3.2 million.

Gangolli's transactions were executed in multiple trades with prices for the sold shares ranging from $163.080 to $166.000. Specifically, 10,930 shares were sold at a weighted average price of $163.7063, while another 7,090 shares were sold at an average of $164.3413. The final batch of 1,980 shares was sold at a weighted average price of $165.7576. The sales were spread across different price points, but the reported figures reflect the weighted average sale prices.

Following these transactions, Gangolli's direct ownership in Krystal Biotech has been reduced to zero, indicating a complete divestment of his previously held non-derivative securities in the company. Additionally, the filing included information about the exercise of options to acquire 20,000 shares of common stock, which were vested monthly over a three-year period starting from March 1, 2019.

The total dollar value for the exercised options amounted to $455,000, with each share priced at $22.75. It is important to note that these options were not part of the final sale total.

Krystal Biotech, Inc., headquartered in Pittsburgh, PA, specializes in developing and commercializing therapies for dermatological diseases. The company's stock performance and insider transactions are closely watched by investors, as they can provide insights into the company's health and the confidence of its leading executives and directors in the firm's future prospects.

Investors and the market at large often scrutinize such sales for indications of an insider's belief in the company's future performance, although such transactions do not always necessarily reflect a change in company outlook as insiders may sell shares for various personal reasons.

InvestingPro Insights

In light of the recent insider trading activity with Julian S. Gangolli selling off his stake in Krystal Biotech, Inc., market participants may be seeking additional data points to understand the company's financial health and future prospects. According to InvestingPro, Krystal Biotech is trading at a high earnings multiple, with an adjusted P/E ratio for the last twelve months as of Q1 2024 at -263.39, which may suggest optimism about the company's future earnings growth despite current losses. The PEG ratio, which stands at 0.61, also indicates potential for earnings growth when considering the price of the stock relative to its earnings growth rate.

Furthermore, Krystal Biotech's gross profit margin impresses at 94.25% for the same period, showcasing the company's ability to maintain profitability on its products. This is complemented by a strong price performance, with a 51.17% total return over the last three months leading up to Y2024.D143, which may reflect investor confidence in the company's strategic direction and operational execution.

For investors looking to delve deeper into the company's metrics, InvestingPro offers additional insights. There are 15 more InvestingPro Tips available, including analyses on the company's cash position, sales growth expectations, and profitability predictions for this year. These tips could provide valuable context for assessing the significance of the director's stock sale and the overall investment thesis for Krystal Biotech. Interested investors can take advantage of a special offer using the coupon code PRONEWS24 to get an extra 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.

Overall, while insider sales can sometimes raise questions about a company's outlook, the robust gross profit margins and positive price performance provide a counterbalance that may reassure investors about Krystal Biotech's potential. The detailed financial analysis and projections available through InvestingPro could further assist in making an informed investment decision.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.